GADOLINIUM-ENHANCED MAGNETIZATION TRANSFER CONTRAST IMAGING OF INTRACRANIAL TUMORS

被引:44
作者
KURKI, TJI
NIEMI, PT
LUNDBOM, N
机构
[1] Department of Diagnostic Radiology, Turku University Hospital, Turku, 20520
来源
JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING | 1992年 / 2卷 / 04期
关键词
ANGIOMA; BRAIN NEOPLASMS; CONTRAST ENHANCEMENT; GADOLINIUM; LOW-FIELD-STRENGTH IMAGING; MAGNETIZATION TRANSFER CONTRAST; MENINGES; NEOPLASMS; PITUITARY; PULSE SEQUENCES;
D O I
10.1002/jmri.1880020408
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The magnetization transfer contrast (MTC) technique was used in low-field-strength (0.1 T) magnetic resonance (MR) imaging of 28 patients with intracranial tumors. MTC images were generated with an off-resonance, low-power radio-frequency pulse applied during the interpulse delay period of a gradient-echo partial-saturation sequence (TR msec/TE msec = 200/20). Images in the presence and absence of the MTC pulse were concurrently acquired before and after injection of gadopentetate dimeglumine at a dose of 0.1 mmol/kg. The contrast agent enhanced 27 of 28 tumors. Application of the MTC pulse improved the contrast-to-noise ratio (C/N) between tumor and normal white matter in 26 of 28 cases on the preinjection images and in 25 of 28 cases on the postinjection images. On the gadolinium-enhanced images, the mean C/N was 2.6 +/- 1.7 without the MTC pulse and 3.2 +/- 1.9 with the MTC pulse. The greatest contrast improvement with the MTC technique was obtained in tumors showing the strongest paramagnetic enhancement. The results indicate that MTC can improve contrast between normal brain and some intracranial neoplasms. The use of gadopentetate dimeglumine generally intensified this effect.
引用
收藏
页码:401 / 406
页数:6
相关论文
共 19 条
[1]  
Felix R, Schorner W, Laniado M, Et al., Brain tumors: MR imaging with gadolinium‐DTPA, Radiology, 156, pp. 681-688, (1985)
[2]  
Brant-Zawadzki M, Berry I, Osaki L, Brasch R, Murovic J, Norman D, Gd‐DTPA in clinical MR of the brain. I. In‐traaxial lesions, AJNR, 7, pp. 781-788, (1986)
[3]  
Berry I, Brant-Zawadzki M, Osaki L, Brasch R, Murovic J, Newton T, Gd‐DTPA in clinical MR of the brain. II. Ex‐traaxial lesions and normal structures, AJNR, 7, pp. 789-793, (1986)
[4]  
Stack JP, Antoun NM, Jenkins JPR, Metcalfe R, Isherwood I, Gadolinium‐DTPA as a contrast agent in magnetic resonance imaging of the brain, Neuroradiology, 30, pp. 145-154, (1988)
[5]  
Haughton VM, Rimm AA, Czervionke LF, Et al., Sensitivity of Gd‐DTPA‐enhanced MR imaging of benign extraaxial tumors, Radiology, 166, pp. 829-833, (1988)
[6]  
Elster AD, Moody DM, Ball MR, Laster DW, Is Gd‐DTPA required for routine cranial MR imaging?, Radiology, 173, pp. 231-238, (1989)
[7]  
Healy ME, Hesselink JR, Press GA, Increased detection of intracranial metastases with intravenous Gd‐DTPA, Radiology, 165, pp. 619-624, (1987)
[8]  
Sze G, Milano E, Johnson C, Heier L, Detection of brain metastases: comparison of contrast‐enhanced MR with un‐enhanced MR and enhanced CT, AJNR, 11, pp. 785-791, (1990)
[9]  
Dean BL, Drayer BP, Bird CR, Et al., Gliomas: classification with MR imaging, Radiology, 174, pp. 411-415, (1990)
[10]  
Wolff SD, Balaban RS, Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo, Magn Re‐son Med, 10, pp. 135-144, (1989)